Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It provides APIs for anti-cancers, peptides, steroids, hormones, and immunosuppressant drugs. In addition, the company offers generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, and antiretrovirals medications, as well as over-the-counter products. The company was founded in 1983 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for SUNPHARMA
Revenue projections for SUNPHARMA

With SUNPHARMA's revenues forecasted to be lower than last year's, investors are expected to be cautious. A decline in revenue typically harms the company's bottom line, reducing profitability and making investors less confident about the company's ability to sustain its financial health.

Financial Ratios:

currentRatio 0.000000
forwardPE 28.602133
debtToEquity 6.675000
earningsGrowth 0.157000
revenueGrowth 0.135000
grossMargins 0.785410
operatingMargins 0.261730
trailingEps 45.530000
forwardEps 56.653120

Sun Pharmaceutical Industries Limited's Forward PE is in a strong range, indicating that its stock price compares well with its earnings. The stock is not considered overpriced, leaving ample room for growth and making it a promising option for investors looking for value and future returns.
SUNPHARMA's positive earnings and revenue growth reflect an optimistic outlook for the company's future. The growth in these key areas indicates that SUNPHARMA is expected to continue expanding its business and boosting its financial performance in the coming periods.
Sun Pharmaceutical Industries Limited's positive gross and operating margins reflect strong profitability and operational efficiency. These metrics indicate the company's ability to control costs while maintaining healthy revenue, contributing to its solid financial performance.
Sun Pharmaceutical Industries Limited's forward EPS surpasses its trailing EPS, reflecting expectations of higher profitability in the current year. This suggests that Sun Pharmaceutical Industries Limited is projected to generate stronger earnings, indicating an optimistic financial outlook compared to the prior year's results.

Price projections:

Price projections for SUNPHARMA
Price projections for SUNPHARMA

Sun Pharmaceutical Industries Limited's stock price has consistently been near the lower edge of expected values, indicating potential struggles in meeting growth projections. This trend may reflect a cautious market sentiment toward the company.

Recommendation changes over time:

Recommendations trend for SUNPHARMA
Recommendations trend for SUNPHARMA


Analysts have shown a buy bias for SUNPHARMA, marking it as a favorable investment option. This could inspire investors to see SUNPHARMA as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.